Comparison tool
Gonadorelin vs Leuprolide side-by-side
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Comparison tool
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Selected (2/4)
Share this peptide comparison
| Property | Gonadorelin | Leuprolide |
|---|---|---|
| Category | Hormonal | Hormonal |
| Also known as | GnRH, LHRH, Factrel | Lupron, Eligard, Leuprorelin |
| FDA approved | Yes | Yes |
| Clinical status | Previously FDA approved as Factrel for diagnostic use; that brand is discontinued, no FDA-approved gonadorelin product is currently marketed in the US, and the source reports availability only as 503A-compounded.
| FDA Approved - Multiple indications
|
| What to expect | Hormone stimulation, fertility, TRT support | Prostate cancer, endometriosis, hormone suppression |
| How it works | Gonadorelin is described as a synthetic GnRH peptide that engages GnRH receptors on gonadotroph cells in the anterior pituitary. The source reports signaling through phospholipase C with calcium and protein kinase C involvement, leading to LH and FSH production and release. Those gonadotropins then influence ovarian or testicular function, including sex-steroid production and gamete development. The source emphasizes pattern of exposure: pulsatile delivery, similar to endogenous GnRH rhythms of about 60 to 120 minutes, supports stimulation, whereas continuous exposure can desensitize and downregulate the receptor and reduce LH and FSH output. | Leuprolide is reported to act as a high-potency agonist at pituitary GnRH receptors. Initial receptor activation can briefly increase LH, FSH, and sex hormones, but sustained exposure desensitizes the pituitary GnRH response and suppresses downstream gonadal hormone production. The source links this hormone-lowering effect to use in androgen- or estrogen-sensitive conditions and notes that the early flare can be clinically relevant. |
| Typical dosing | 100-500 mcg 2-3x weekly · 2-3x weekly · IV, subcutaneous, or pulsatile pump | Variable - depends on formulation · Daily, monthly, or every 3-6 months |
| Research dosing | 100 mcg IV/SC for diagnostic testing · Single dose (diagnostic) or ongoing (therapeutic) · IV, subcutaneous, or pulsatile pump | 7.5mg monthly depot · Months to years depending on indication · Intramuscular or subcutaneous depot injection |
| Typical duration | Single dose (diagnostic) or ongoing (therapeutic) | Months to years depending on indication |
| Administration | IV, subcutaneous, or pulsatile pump | Intramuscular or subcutaneous depot injection |
| Timing | Morning or as clinically directed With or without food | Morning or as directed With or without food |
| Evidence level | FDA Approved | FDA Approved |
| Possible side effects |
+4 more
|
+5 more
|
| Research summary | The source frames gonadorelin as an established GnRH molecule rather than an experimental novelty. Diagnostic GnRH stimulation testing is described as established, and pulsatile pump administration is reported in hypogonadotropic hypogonadism, delayed puberty, and fertility induction. Because the peptide is short-lived, the source notes that historical clinical use depended on pumps or frequent administration, while longer-acting GnRH agonists later displaced some uses. The source also describes off-label TRT-adjunct use as common in some clinic and online settings, but supported mainly by mechanism, small-scale experience, or anecdote rather than large randomized comparisons showing superiority over HCG. | The supplied evidence frames Leuprolide as a long-established FDA-approved GnRH agonist with clinical use rather than as an exploratory research peptide. It reports approval dating to 1989 and describes evidence in prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. The same source emphasizes that its benefits are tied to reversible suppression of sex-hormone production, while many important adverse effects arise from that low-hormone state, including hot flashes and bone-density concerns with longer exposure. |
| References | ||
| Full profile | View Details | View Details |
Save this comparison
Keep this research set handy with a free PeptiGuide account.
Save this comparison - free accountTrack your peptide journey
Turn research into a private protocol log when you are ready.
Track your peptide journeyEducational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.